GlaxoSmithKline to Buy Stake in Intercell AG
GlaxoSmithKline Plc will buy a stake in Austria’s Intercell AG in a move that analysts said underscores drugmakers’ growing interest in vaccines. Glaxo will pay 33.6 million euros ($49.5 million) as part of the alliance to develop and market Intercell’s needle-free, patch-based immunizations for traveler’s diarrhea and pandemic influenza. The London-based drugmaker also will buy as much as 5 percent of Intercell for up to 84 million euros via a staggered shareholding option, the companies said in a statement today.
XTractor Premium - A Platform for discovery, knowledge sharing, analysis and modelling of published biomedical facts.
XTractor Premium - A Platform for discovery, knowledge sharing, analysis and modelling of published biomedical facts.
- The only Knowledgebase which provides "manually" annotated facts from PubMed on a weekly basis
- Innovative Features like Semantic Search, Concept Linking, Bibliographic search, Save, Export and Visualize
- Only Knowledgebase with daily updations from PubMed
- XTractor Premium now at an Special Introductory Offer. Subscribe now and save!
- Request for a Trial
Comments